Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Ratio (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Equity Ratio data on record, last reported at 0.88 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 4.61% year-over-year to 0.88; the TTM value through Dec 2025 reached 0.88, down 4.61%, while the annual FY2025 figure was 0.88, 4.61% down from the prior year.
  • Equity Ratio reached 0.88 in Q4 2025 per CRNX's latest filing, down from 0.9 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.95 in Q4 2021 and bottomed at 0.85 in Q4 2023.
  • Average Equity Ratio over 5 years is 0.9, with a median of 0.9 recorded in 2022.
  • Peak YoY movement for Equity Ratio: decreased 6.48% in 2023, then increased 8.83% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.95 in 2021, then decreased by 5.02% to 0.9 in 2022, then dropped by 5.53% to 0.85 in 2023, then grew by 8.83% to 0.92 in 2024, then dropped by 4.61% to 0.88 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.88 in Q4 2025, 0.9 in Q3 2025, and 0.91 in Q2 2025.